Dr. Daniel Mulkerin, MD
Claim this profileUniversity of Rochester Medical Center
Studies Stomach Cancer
Studies Pancreatic Cancer
2 reported clinical trials
4 drugs studied
Area of expertise
1Stomach Cancer
Stage IV
Stage III
2Pancreatic Cancer
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Daniel Mulkerin, MD is currently running
SX-682 + Nivolumab
for Pancreatic Cancer
The main purpose of this research study is to determine the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic ductal adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression.
Recruiting1 award Phase 116 criteria
Immunotherapy
for Pancreatic Cancer
This trial will assess the safety and tolerability of Pepinemab in combination with Avelumab in patients with metastatic pancreatic adenocarcinoma that has progressed after first line chemotherapy. Phase 2 will assess the efficacy of this combination therapy.
Recruiting1 award Phase 1 & 220 criteria
More about Daniel Mulkerin, MD
Clinical Trial Related4 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Daniel Mulkerin, MD has experience with
- Nivolumab
- SX-682
- Avelumab
- Pepinemab
Breakdown of trials Daniel Mulkerin, MD has run
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Mulkerin, MD specialize in?
Daniel Mulkerin, MD focuses on Stomach Cancer and Pancreatic Cancer. In particular, much of their work with Stomach Cancer has involved Stage IV patients, or patients who are Stage III.
Is Daniel Mulkerin, MD currently recruiting for clinical trials?
Yes, Daniel Mulkerin, MD is currently recruiting for 2 clinical trials in Rochester New York. If you're interested in participating, you should apply.
Are there any treatments that Daniel Mulkerin, MD has studied deeply?
Yes, Daniel Mulkerin, MD has studied treatments such as Nivolumab, SX-682, Avelumab.
What is the best way to schedule an appointment with Daniel Mulkerin, MD?
Apply for one of the trials that Daniel Mulkerin, MD is conducting.
What is the office address of Daniel Mulkerin, MD?
The office of Daniel Mulkerin, MD is located at: University of Rochester Medical Center, Rochester, New York 14642 United States. This is the address for their practice at the University of Rochester Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.